Ole O Thomsen
Overview
Explore the profile of Ole O Thomsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bendtzen K, Steenholdt C, Brynskov J, Thomsen O, Ainsworth M
Frontline Gastroenterol
. 2017 Aug;
7(2):152-154.
PMID: 28839850
No abstract available.
2.
Buhl S, Steenholdt C, Rasmussen M, Borghede M, Brynskov J, Thomsen O, et al.
Inflamm Bowel Dis
. 2017 Apr;
23(7):1210-1217.
PMID: 28445244
Background: Primary infliximab treatment failure is common in patients with inflammatory bowel disease and represents a challenge to clinicians. Treatment options are limited. This study assessed the prognosis, defined as...
3.
Edlund H, Steenholdt C, Ainsworth M, Goebgen E, Brynskov J, Thomsen O, et al.
AAPS J
. 2016 Oct;
19(1):223-233.
PMID: 27739011
Antibodies (Abs) against infliximab (IFX) increase IFX clearance and can result in treatment failure and acute hypersensitivity reactions. However, interpretation of their clinical value is complicated by individual differences in...
4.
Steenholdt C, Brynskov J, Thomsen O, Munck L, Christensen L, Pedersen G, et al.
J Crohns Colitis
. 2015 Aug;
9(11):1032-42.
PMID: 26245216
Background: This study assessed the effects of infliximab (IFX) treatment failure on patient-reported outcomes and explored the influence of using personalized treatment in this situation. Methods: Sixty-nine Crohn's disease patients...
5.
Steenholdt C, Frederiksen M, Bendtzen K, Ainsworth M, Thomsen O, Brynskov J
J Clin Gastroenterol
. 2015 Jul;
50(6):483-9.
PMID: 26166141
Background: Antibodies (Abs) against adalimumab (ADL) have been associated with low ADL levels and treatment failure. Aim: To characterize the temporal characteristics of anti-ADL Ab appearance and possible disappearance, and...
6.
Christensen K, Steenholdt C, Buhl S, Ainsworth M, Thomsen O, Brynskov J
Am J Gastroenterol
. 2015 Jun;
110(11):1526-32.
PMID: 26032156
Objectives: Implementation of guidelines for prevention of infectious diseases during anti-TNFα therapy in patients with inflammatory bowel disease (IBD) is important but difficult. We investigated whether systematic information to health-care...
7.
Steenholdt C, Brynskov J, Thomsen O, Munck L, Fallingborg J, Christensen L, et al.
Dig Dis Sci
. 2015 Feb;
60(9):2762-70.
PMID: 25673037
Background: In Crohn's disease patients failing infliximab therapy, interventions defined by an algorithm based on infliximab and anti-infliximab antibody measurements have proven more cost-effective than intensifying the infliximab regimen. Aim:...
8.
Steenholdt C, Bendtzen K, Brynskov J, Thomsen O, Munck L, Christensen L, et al.
J Crohns Colitis
. 2015 Jan;
9(3):238-45.
PMID: 25576753
Background And Aims: Intensification of the infliximab (IFX) regimen is recommended if the treatment effect is inadequate. However, the rationale for this is not well defined as the underlying mechanisms...
9.
Steenholdt C, Bendtzen K, Brynskov J, Thomsen O, Ainsworth M
Am J Gastroenterol
. 2014 May;
109(7):1055-64.
PMID: 24796769
Objectives: Cost-effective guidance of therapeutic strategy in Crohn's disease patients with secondary infliximab (IFX) treatment failure may be achieved by serum IFX and anti-IFX antibody (Ab) measurements by radioimmunoassay (RIA)....
10.
Steenholdt C, Ainsworth M, Tovey M, Klausen T, Thomsen O, Brynskov J, et al.
Ther Drug Monit
. 2013 Jun;
35(4):530-8.
PMID: 23765033
Background: Several techniques are used to measure infliximab (IFX) and anti-IFX antibodies (Abs) in Crohn's disease. The aim of this study was to compare different assays for this purpose. Methods:...